Dr. Alamuri is a senior research and project management professional with over a decade of relevant experience. He received his PhD from the University of Georgia. After his post-doctoral fellowship work in microbiology and vaccines at University of Michigan, Dr. Alamuri joined Arizona State University's (ASU) Biodesign Institute in Tempe, AZ, where he was part of a leadership team that helped to expand the university's relationships with industry, secure grant funding, and expand intellectual property positions. Dr. Alamuri was directly involved in laboratory operation, and research design and development of engineered Salmonella vaccines for human and veterinary vaccines to protect against infectious diseases (TB, Plague, Influenza). Dr. Alamuri published 14 research articles, including 2 reviews. He also received MBA in Strategy and Product Development at the W. P. Carey School of Business at ASU.
Dr. Barrett is an accomplished medical oncologist and R&D expert with more than 30 years of clinical and research experience in leadership positions at major institutions in industry and academia. He has spent the last decade gaining broad expertise in the fields of target and drug discovery, most recently, as executive director/ lead of global medical affairs for targeted oncolytic therapies at Incyte Pharmaceuticals. Dr. Barrett is a trained physician-scientist, earning his bachelor’s degree at The Johns Hopkins University as a Beneficial-Hodson Scholarship recipient. He then earned his medical degree from the University of Miami School of Medicine and completed his internal medicine residency at the Mayo Clinic in Rochester, Minn. At Memorial Sloan-Kettering Cancer Center, Dr. Barrett completed his fellowship in medical oncology where he co-authored a Phase 2, proof-of-concept study, which pioneered the use of paclitaxel for advanced breast cancer treatment in the ambulatory setting. Prior to entering the biopharmaceutical industry, he practiced academic and community-based hematology/oncology for 15 years. Dr. Barrett is board-certified in both internal medicine and in medical oncology.
Dr. Battula is a highly passionate scientific leader with expertise in the areas of immuno-oncology (IO), inflammation and autoimmunity. She is an experienced scientist previously leading projects at Applied Immunology, FORMA Therapeutics, Inc. and most recently as associate director of immuno-oncology at Bicycle Therapeutics. She performed postdoctoral research at U.C. San Francisco after earning her Ph.D. in Pharmacology from New York Medical College.
Dr. Brothers is a Bioinformatician with expertise in NGS data analysis and specializes in transcriptomics. He brings industry experience with working in team-based collaborative environments with clinicians, experimentalists, and bioinformaticists. He graduated with a B.S. in Bioinformatics from the Rochester Institute of Technology and a Ph.D. in Bioinformatics from Boston University. His doctoral thesis focused on identifying splice variants and novel genes associated with chronic lung disease in order to better characterize the lung transcriptome from patients with chronic obstructive pulmonary disease or idiopathic pulmonary fibrosis.
Since joining Immuneering, Ms. Cha has developed an expertise in multi-omic integration and mutation prioritization in cancer data. She holds a B.S. in Computer Science and Molecular Biology from the Massachusetts Institute of Technology. Before graduating, she spent a year at the Bioinformatics Institute at Seoul National University working on a method to identify differentially expressed signaling pathways. She also spent a summer at the Robert Koch Institute in Berlin, Germany, analyzing genomic and proteomic data from viruses. She won first place in the 10th Annual Merck/BE-BMES Undergraduate Research Poster Session.
Dr. Escalante-Chong is passionate about integrating the massive amounts of data generated in modern biology to transform disease management and treatment. He did his Ph.D. at the Department of Systems Biology at Harvard Medical School where he used quantitative molecular genetics to dissect signaling pathways. He completed his postdoctoral training at the Department of Biological Engineering at the Massachusetts Institute of Technology where he worked with the interdisciplinary teams of neuroLINCS and answerALS to generate molecular signatures of the neurodegenerative diseases ALS and SMA.
Dr. Fowler brings deep expertise in biology and computational biology to our team. He joined Immuneering after completing his Ph.D. in Chemical Engineering at the Massachusetts Institute of Technology. His doctoral research was focused on computational immunology and signal integration in immune cell biology, and he conducted research at Harvard Medical School.
Dr. Funt’s focus is in synthesizing actionable insight from complex, heterogeneous high-dimensional data. He earned his Ph.D. in Computational and Systems Biology from MIT’s Biology Department. His thesis research, at both the Massachusetts Institute of Technology and the Broad Institute, focused on mapping evolutionary pathways of drug resistance from genomic and transcriptomic profiling of the pathogen Candida albicans.
Dr. Hall is a pharmaceutical and biotechnology veteran (Janssen/J&J; Medimmune/AZ, Molecular Response; Asellus Therapeutics) with extensive drug development and leadership experience ranging from early drug discovery through translational clinical sciences including multiple drug registrations. He was the translational lead for Sylvant® (siltuximab) and Imbruvica® (ibrutinib) throughout clinical development, and his translational medicine teams developed and executed translational strategies for both Darzalex® (daratumumab) and Imfinzi® (durvalumab). Dr. Hall has extensively published in the areas of tumor microenvironment (TME) and translational sciences and holds multiple patents for drug pharmacology and discovery. Prior to his experience in the life sciences industry, Dr. Hall served in the United States Air Force and worked as a Series 6 and 63 licensed investment banker. After completing his graduate and postdoctoral studies, Dr. Hall was a tenure-track assistant professor at Ohio State University where his laboratory focused on development of human TME-aligned models to better translate preclinical data into the clinic and discover novel biomarkers.
Dr. Kagalwala straddles neuroscience R&D and business leadership experience to develop innovative therapeutics for aging neurodegenerative disorders. He has extensively published high impact research in peer-reviewed journals. Prior to joining Immuneering, he co-founded Siragen Pharmaceuticals, where he led the small molecule drug discovery program for Alzheimer’s disease, from target identification through proof of concept, and lead optimization. Dr. Kagalwala completed his Ph.D. in Biochemistry at SIU School of Medicine (dissertation on chromatin remodeling), and then post-doctoral training at MD Anderson Cancer Center (Glioblastoma / Medulloblastoma), and the Salk Institute (adult neurogenesis and neurodegeneration). In 2015, he also earned an MBA at Rady School of Management, UC San Diego, where he was awarded the prestigious Foster fellowship, and recognized as a Rady Innovation Fellow for business assistance to technology acceleration and commercialization programs.
Dr. Kaufman is a leading authority on tumor immunotherapy with a distinguished career in academia and industry. His major accomplishments include pioneering work to develop the first oncolytic virus approved for the treatment of advanced melanoma and a novel programmed cell death ligand 1 (PD-L1) inhibitor as the first drug ever approved for the treatment of patients with Merkel cell carcinoma. Dr. Kaufman has published more than 500 peer-reviewed abstracts, scientific/clinical manuscripts and book chapters. His industry leadership roles have included scientific and advisory boards at Amgen, Bristol-Myers Squibb, EMD Serono/Merck KGaA, Merck, Sanofi and he served as chief medical officer at Compass Therapeutics and Replimune, Inc. His academic leadership includes service as director of the Rush University Cancer Center and was chief of the division of surgical oncology and associate cancer center director at Columbia University as well as the Rutgers Cancer Institute of New Jersey. He held the Weiskopf endowed associate professorship at Columbia University and was tenured full professor at Rush Medical School and Rutgers University. His professional contributions include major leadership roles at the American Cancer Society, American Association of Cancer Research, American Society of Clinical Oncology, Commission on Cancer, Society of Surgical Oncology and the Society for Immunotherapy of Cancer and has served as President. Dr. Kaufman has been the recipient of several awards, including the Daland Prize, the Humanitarian Award of the Melanoma Research Foundation and the UIC Distinguished Alumnus Award. Dr. Kaufman is board certified and maintains a small clinical practice at the Massachusetts General Hospital. He also has an appointment at the Harvard Medical School.
Mr. Kim is passionate about utilizing technology to accelerate research and development in the field of biomedicine. Prior to obtaining his M.S. in Biomedical Informatics from the Sackler Institute of Graduate Biomedical Sciences at NYU School of Medicine, he spent over five years working as a software implementation consultant specializing in the life sciences industry, where he led projects to configure, deploy, and manage the enterprise software development life cycle. He also graduated with a B.S./M.S. in Biomedical Engineering from Northwestern University.
Dr. King is a pharmaceutical professional with over 16 years of drug discovery and development experience (Janssen R&D/Johnson & Johnson; SmithKLine Beecham). With experience ranging from early drug discovery and preclinical/translational sciences. Dr King gained his B.Sc. from the University of Leicester, UK, in Biological Sciences in 1996, and his Ph.D. in Diabetes and Endocrinology in 2000, from the University of Liverpool, UK. After 2 years of postdoctoral training, Dr King joined Janssen Pharmaceuticals in 2002 at the Beerse site in Belgium, as a Scientist and Senior Scientist, in the Metabolic Disorders and Oncology Teams. He led the preclinical oncology in vivo team, where he contributed to numerous NME declarations and IND filings. As part of the Oncology Biomarkers Team, he was responsible for the Ex Vivo Center of Excellence for humanized model development. In 2012, Dr King joined the Molecular Imaging Team at the Janssen Spring House site in USA and lead the imaging program to support the Oncology Therapeutic Area.
Dr. Kolitz brings expertise in teasing apart biological mechanisms to our team. She conducted her postdoctoral research in Biological Engineering at the Massachusetts Institute of Technology, after earning a Ph.D. in Biophysics and Biophysical Chemistry from the Johns Hopkins University School of Medicine.
Dr. Krishnan brings expertise in understanding cellular responses to protein misfolding events and developing therapies to mitigate toxicity associated with these conditions. Over the last decade he was involved in designing Ig-fusion-based therapeutics to treat Alzheimer’s disease and Systemic Amyloidosis. Prior to joining the biotech industry, he conducted his postdoctoral research at the Whitehead Institute of Biomedical Research (MIT) and earned a PhD in Biophysics and Molecular Biology from the Center for Cellular and Molecular Biology, Hyderabad, India.
Dr. Kusko is a computational biologist with expertise in translating NGS and other genomic data to clinical discoveries and actionable insights. In five years at Immuneering, Dr. Kusko has published 14 journal articles and three textbook chapters spanning best practices, neurodegeneration, oncology, computational toxicology, drug mechanism of action and biomarker development. She is a founding member and current deputy board chairperson of the FDA-led Massive Analysis and Quality Control (MAQC) Society. Dr. Kusko has integrated directly with clinicians on study design, as well as with lab scientists in functional genomics, to plan molecular biology and validation experiments. After completing her undergraduate degree in biological engineering at the Massachusetts Institute of Technology (MIT), she went on to complete her Ph.D. in computational biomedicine at the Boston University School of Medicine where her doctoral thesis focused on the transcriptome in chronic obstructive pulmonary disease (COPD) and lung cancer in never-smokers. Dr. Kusko is a guest lecturer at MIT and Boston University.
Dr. Lysaght integrates years of experience with biological expression data together with a rigorous background in engineering fundamentals to provide expertise in customized data analysis with an eye for practical and actionable results. He earned a Ph.D. from the joint Harvard-MIT Program in Health Sciences and Technology, where he worked alongside leading clinicians of the Massachusetts Eye and Ear Infirmary to identify changes in inner ear transcription and translation during delayed onset hearing loss.
Ms. Martin has several years of experience in office administration in various industries, as well as a broad background in customer relations, social media and marketing, human resources and recruiting, and finance. She holds a B.S. in Communications from Fitchburg State University.
For over a decade, Dr. Ross studied at the National Institutes of Health, where he designed and conducted original research in the field of bioinformatics and comparative genomics. His work has been recognized for enhancing computational methods to identify and analyze molecular mechanisms that regulate neurogenesis. Dr. Ross has developed and employed machine learning and bioinformatic algorithms to decode the combinatorial logic of noncoding DNA that control gene expression programs. He earned his Ph.D. degree in Neuroscience from Brown University.
Dr. Shrimali is an accomplished immunologist and immune therapist bringing over 15 years of expertise in the field of Immuno-Oncology (IO). His research interest and expertise include tumor microenvironment (TME) and immune regulation, immune check point inhibitors / co-stimulators, development of biologics and targeted cancer immune therapies and identification of clinical biomarkers. His major endeavor involves development of corrective combinational cancer therapies and delineating their cellular and molecular immune potentiating mechanism of action. His published research highlights the significance of timing and sequence of targeting various immune checkpoints and the immune context of the TME, that can determine the therapeutic outcome. He received his Ph.D. in biochemistry from Indian council of medical research, Mumbai university, India. During his postdoctoral training, he had the privilege to work with Dr. Steven A. Rosenberg at NCI / NIH, the pioneer in the field of cancer immunotherapy. Following that, he has held various scientific and leadership positions as senior scientist, group leader and Director IO at some of the most esteemed organizations including Aurigene Discovery Technologies Ltd., Peloton Therapeutics and MD Anderson Cancer Center. In above positions, he has been the immunology lead of various oncology and inflammation programs right from early target discovery through IND filing and further out licensing or patient trials of clinical candidate.
Outside work he enjoys spending time in traveling with his family, Indian cooking, stage / theater acting and hosting live radio shows.
Dr. Ung is a computational biologist with extensive experience in applying data science techniques to extract translational insight from biological and disease data. Dr. Ung received his Ph.D. from the Geisel School of Medicine at Dartmouth in the Department of Molecular and Systems Biology. During this time, he primarily focused on developing computational approaches to integrate diverse genomic and clinical datasets to pinpoint the genetic aberrations underlying several cancer types and to identify potential therapeutic candidates. In addition, Dr. Ung’s interdisciplinary background has allowed him to author and co-author several studies across diverse topics including experimental pharmacology, epidemiology, epigenetics, and biological networks.
Dr. Zeskind co-founded Immuneering in 2008 with the goal of leveraging high-throughput data to improve pharma R&D. He is an inventor on numerous patents assigned to both Immuneering's partners and the company itself. Dr. Zeskind has published extensively in high-impact peer-reviewed journals. He trained at the Massachusetts Institute of Technology, earning a Ph.D. in Bioengineering in 2006 and an S.B. in electrical engineering and computer science in 2003. He also earned an MBA at Harvard Business School in 2008, where he was recognized as a Baker Scholar, the highest award for distinction.
Dr. Zhang extracts actionable insights from genomic data by combining cutting-edge data science techniques with expertise in experiment design and cancer biology. During her data science fellowship at The Data Incubator, she utilized distributed computing, network analysis, and machine learning to reveal patterns within large textual and numerical datasets. She graduated from the Massachusetts Institute of Technology with a B.S. in Physics, and Duke University with a Ph.D. in Genetics and Genomics. In her doctoral work, she developed novel experimental and bioinformatic methods to generate and analyze terabytes of next-generation sequencing data towards understanding the mutational underpinnings of lymphoma.
Mr. Carpenter is a leader and pioneer in the healthcare and biotechnology industries. He served on Genzyme’s board of directors from 1994-2011 and was executive vice president of Genzyme from 1989-1991 as well as chairman of its subsidiary IG Laboratories. He founded and served in executive management and board roles at numerous biotech companies, including Integrated Genetics and GelTex Pharmaceuticals, both of which merged with Genzyme, and VacTex, which was acquired by Aquila Biopharmaceuticals. Mr. Carpenter is currently chairman of Hydra Biosciences. Mr. Carpenter is a graduate of West Point. He earned his master’s degree in computer science from Stanford University and his MBA from Harvard Business School.
Mr. Kekst is a founding member of Boxcar Partners, a venture capital investment firm comprised of several family offices with a focus area in biotech investing. He serves on the board of advisors at The Jewish Theological Seminary and is a board member at the Weizmann Institute of Science. He is also a founder of Sporos Bioventures. Mr. Kekst earned his bachelor’s degree from Brandeis University.
Mr. Feinberg has more than three decades of experience in the financial services industry at Oppenheimer & Co. He is a founding member of Boxcar Partners, a venture capital investment firm comprised of several family offices with a focus area in biotech investing. He is a founder of multiple companies including BridgeBio, which invests in preclinical, non-public, rare genetic disease assets, North Coast Partners, a real estate holding company that invests in Detroit. He is an advisory board member of Ignite Power, an African solar energy company, currently the largest in Rwanda, which has created a life changing experience for its citizens and Sporos Bioventures. Mr. Feinberg earned his bachelor’s degree in finance from Whittier College.
Computational Biology Advisory Board
Dr. Artyomov is an assistant professor of immunology and pathology at Washington University in St. Louis. His research is focused on developing an integrated experimental and computational pipeline to address important biological problems by leveraging the power of next-generation sequencing. His approach combines the power of systems immunology with high-throughput sequencing, mathematical modeling and statistical physics. Dr. Artyomov earned a Ph.D. in chemistry at the Massachusetts Institute of Technology (MIT) with a focus on computational immunology before conducting his postdoctoral research at the Broad Institute of Harvard and MIT.
Dr. Lauffenburger is the head of the department of biological engineering at the Massachusetts Institute of Technology and a pioneer in applying engineering principles to biological research. His expertise spans multiple disciplines including chemical engineering, bioengineering, biotechnology process engineering, biophysics, quantitative cell and structural biology, systems biology and applied mathematics. He has filed numerous patents, authored a key textbook on receptor-ligand binding and trafficking dynamics and published more than 200 peer-reviewed articles.
Oncology Advisory Board
Dr. Ahn is an assistant professor at the Mayo Clinic and is the director of the GI Oncology Translational Research Working Group. He is a member on the Academic and Community Cancer Research United (ACCRU) Board of Directors. Dr. Ahn is an experienced clinical study program leader and is well-positioned to provide clinical insights into the predicted therapeutic index (efficacy vs safety) across early-stage compounds in this treatment space. His peer reviewed publications focus around early therapeutic clinical trials in GI-Oncology and he is well-recognized as a sub-specialist in hepatobiliary malignancies.
Dr. Baracos is a professor in the department of oncology at the University of Alberta. Dr. Baracos has been studying cachexia for more than 30 years and her clinical research is focused on the underlying causes of muscle wasting in cancer patients including the role of tumor progression, specific drugs used in cancer therapy such as sorafenib and of a putative muscle proteolysis-inducing factor. As a senior author of the international consensus framework for definition of cancer cachexia, Dr. Baracos provides insight into how cachexia is best measured and quantified in patients. Dr. Baracos has made numerous contributions to the understanding of the mechanisms of cancer-associated cachexia and muscle wasting using standardized animal models.
Dr. Bekaii-Saab is a professor of medicine at the Mayo Clinic and leads the Mayo Clinic-supported cancer research consortium Academic and Community Cancer Research United (ACCRU). He is a leading clinician-scientist in the Alliance for Clinical Trials in Oncology, a National Cancer Institute (NCI)-supported cooperative research group. Dr. Bekaii-Saab was a key author on two clinical manuscripts describing the muscle preservation benefits of MEK inhibition for cancer cachexia. Dr. Bekaii-Saab provides a clinician’s perspective on MEK inhibitors for cancer cachexia.
Dr. Borad is the director of the Cancer Cell, Gene, and Virus (CGV) Therapy lab at the Mayo Clinic Center for Individualized Medicine (CMI). He is a top-tier researcher, educator and clinician having served as director of the CGV Lab and director of the Liver & Biliary Cancer Research Program at the Mayo Clinic. He has also held the position of vice-chair of the International Cholangiocarcinoma Research Network (ICRN) of the Cholangiocarcinoma Foundation. Dr. Borad is the co-chair of the Mayo Clinic Hepatobiliary Cancers CME-accredited International Review Symposium.
Dr. Del Fabbro is the Palliative Care Endowed Chair and Program Director at Virginia Commonwealth University Health. He is a member of the Richmond Academy of Medicine and serves on the board of Honoring Choices Virginia. Dr. Del Fabbro directed a cachexia clinic from 2005-2011 and is the lead author on a clinical handbook on cancer cachexia. He provides guidance on the clinical impact of cancer cachexia as well as cancer cachexia diagnosis, patient assessment, current management techniques, and monitoring.
Dr. Guttridge is the director of the Charles P. Darby Children’s Research Institute and associate director of translational sciences for Hollings Cancer Center at the Medical University of South Carolina (MUSC). Dr. Guttridge's research focuses on the cancer syndrome cachexia which contributes to poor prognosis and a reduced quality of life. He has also led cancer cachexia and pancreatic cancer programs. His other research interests include pancreatic cancer and childhood illnesses related to skeletal muscle defects including Duchenne muscular dystrophy and a childhood cancer called rhabdomyosarcoma. Dr. Guttridge is the senior author on a key publication showing the effectiveness of MEK inhibitors in a cancer cachexia mouse model and brings his expertise in cancer cachexia molecular biology, muscle biology and in vivo models.
Dr. Nejadnik is chief medical officer and head of research at SanBio, Inc. Dr. Nejadnik has more than two decades of experience in large pharma and small biotech companies. He has led research teams in academic institutions and programs from early phase to registration trials, with successful BLA/NDA/MAA submissions and market launch. He was teaching faculty at University of California and Stanford University. He held multiple key roles at Johnson & Johnson working on numerous compounds in early and late stage registrational trials in Alzheimer diseases immunology, autoimmune disorders, hematology and oncology. He previously served as executive director at Jazz Pharmaceuticals where he led the clinical team towards an approved biologic license application (BLA) and was the lead of medical affairs division, overseeing the launch of newly approved agents in their portfolio. Dr. Nejadnik earned his undergraduate degree and M.D. from the University of Louvain in Belgium.
Dr. Roeland is a faculty member at Massachusetts General Hospital (MGH). His research spans both palliative care and medical oncology with a focus on gastric cancer. He serves as the American Society of Clinical Oncology Co-Chair for the Supportive Care and Cachexia/Nutrition Guidelines Committees. Dr. Roeland is an experienced clinician with valuable insights into clinical trial design and patient recruitment.
Dr. Sawyer is a professor in the department of oncology at the University of Alberta. Dr. Sawyer has published extensively in the cancer cachexia space including both research articles and reviews. Dr. Sawyer was a key author together with Dr. Bekaii-Saab on two publications assessing the clinical benefit of MEK inhibitors for cancer cachexia patients. Dr. Sawyer provides valuable insights in comparing and contrasting existing MEK inhibitors, relevant indications and toxicity.
Dr. Zimmers is a professor of cancer research at the Indiana University (IU) School of Medicine. She is the founding director of the IU Simon Cancer Center Cachexia Working Group and the IUPUI Center for Cachexia Research Innovation and Therapy. Through multi-disciplinary collaboration, these groups seek to improve diagnosis, treatment and educational outreach for patients with cachexia. Dr. Zimmers is experienced in high-throughput profiling of cancer cachexia and provides guidance on the molecular biology.